In agreement with the results from our previous research [1], the flow cytometry analysis revealed elevated ratios of CD8+ effector T cells, CD4+ memory T cells, and CD8.+ memory T cells in OMV-P-treated mice, which suggests ESC-based epitopes have the potential to inhibit different types of tumor growth via inducing antitumor T cell responses. This evidence concerns the gene CD8A and neoplasm.